COVID-19

16 competing products in clinical development for COVID-19.

Pipeline by Phase

Phase 11

Phase 210

Phase 33

Approved1

Preclinical1

All Products (16)

Product	Company	Stage	Status	Hype
Bamlanivimab + Placebo + Etesevimab	Eli Lilly	Phase 3	Completed	40
Infliximab	Celltrion	Phase 2	Completed	35
S-892216 + Placebo	Shionogi	Phase 2	Completed	35
Desidustat	Zydus Lifesciences	Phase 2	Completed	35
Gimsilumab + Placebo	Roivant Sciences	Phase 2	Completed	32
CT-P63 and CT-P66 / Placebo	Celltrion	Phase 3	Withdrawn	32
Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo	Sinopharm	Phase 2	UNKNOWN	31
Mavrilimumab + Placebo	Kiniksa Pharmaceuticals	Phase 2	Completed	29
Mavrilimumab + Placebos	Kiniksa Pharmaceuticals	Phase 2	Completed	29
Mavrilimumab + Placebos	Kiniksa Pharmaceuticals	Phase 2	Completed	29
S-892216 + Carbamazepine	Shionogi	Phase 1	Completed	29
Enzalutamide Pill	Astellas Pharma	Phase 2	Terminated	27
Icosapent ethyl	Amarin Corporation	Phase 2	Completed	25
mRNA-1283.251 Variant-containing Formulation	Moderna	Approved	Recruiting	0
mRNA-1283.222	Moderna	Phase 3	Completed	0
Moderna COVID-19 Vaccine	Moderna	Preclinical	Completed	0